Opdivo plus Yervoy continues to demonstrate a clinically meaningful survival benefit vs. chemotherapy with the longest follow-up of any Phase 3 trial for an immunotherapy combination in non-small cell lung cancer
Increased overall survival and improvements in key secondary endpoints observed at four years in the primary population of patients whose tumors express PD-L1 ≥1%
In exploratory analyses of patients with PD-L1 expression